Selumetinib for the treatment of non-small cell lung cancer

References

• Riely GJ, Marks J, Pao W. KRAS mutations in non-small cell lung cancer. Proc Am Thorac Soc. 2009;6:201–205.
   PubMedGoogle Scholar
• Vasan N, Boyer JL, Herbst RS. A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res. 2014;20(15):3921–3930.
   PubMed Web of Science ®Google Scholar
• Karachaliou N, Mayo C, Costa C, et al. KRAS mutations in lung cancer. Clinical Lung Cancer. 2013;14:205–214.
   PubMed Web of Science ®Google Scholar
• Roberts PJ, Stinchcombe TE, Der CJ, et al. Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy? J Clin Oncol. 2010;28(31):4769–4777.
   PubMed Web of Science ®Google Scholar
• Le Calvez F, Mukeria A, Hunt JD, et al. TP53 and KRAS mutation load and types in lung cancers in relation to tobacco smoke: distinct patterns in never, former, and current smokers. Cancer Res. 2005;65:5076–5083.
   PubMed Web of Science ®Google Scholar
• Available from: https://cancergenome.nih.gov/abouttcga
   Google Scholar
• Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the catalogue of somatic mutations in cancer. Nucleic Acids Res. 2011;39:D945–D950.
   PubMed Web of Science ®Google Scholar
• Ihle NT, Byers LA, Kim ES, et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst. 2012;104(3):228–23915.
   PubMed Web of Science ®Google Scholar
• Sousa SF, Fenandes PA, Ramos MJ. Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem. 2008;15:1478–1492.
   PubMed Web of Science ®Google Scholar
• Graziano SL, Gamble GP, Newman NB, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol. 1999;17:668–675.
   PubMed Web of Science ®Google Scholar
• Lu C, Soria JC, Tang X, et al. Prognostic factors in resected stage I non-small-cell lung cancer: a multivariate analysis of six molecular markers. J Clin Oncol. 2004;22:4575–4583.
   PubMed Web of Science ®Google Scholar
• Keohavong P, de Michele MA, Melacrinos AC, et al. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res. 1996;2:411–418.
   PubMed Web of Science ®Google Scholar
• Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med. 1990;323:561–565.
   PubMed Web of Science ®Google Scholar
• Fukuyama Y, Mitsudomi T, Sugio K, et al. K-ras and p53 mutations are an independent unfavorable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer. 1997;75:1125–1130.
   PubMed Web of Science ®Google Scholar
• Huang CL, Taki T, Adachi M, et al. Mutations of p53 and K-RAS genes as prognostic factors for non-small cell lung cancer. Int J Oncol. 1998;12:553–563.
   PubMed Web of Science ®Google Scholar
• Miyake M, Adachi M, Huang C, et al. A novel molecular staging protocol for non-small cell lung cancer. Oncogene. 1999;18:2397–2404.
   PubMed Web of Science ®Google Scholar
• Nelson HH, Christiani DC, Mark EJ, et al. Implications and prognostic value of K-RAS mutation for early-stage lung cancer in women. J Natl Cancer Inst. 1999;91:2032–2038.
   PubMed Web of Science ®Google Scholar
• Guerrero S, Casanova I, Farre L, et al. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res. 2000;60:6750–6756.
   PubMed Web of Science ®Google Scholar
• Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55:4575–4580.
   PubMed Web of Science ®Google Scholar
• Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with “KRAS addiction” reveals regulators of EMT and tumor cell curvival. Cancer Cell. 2009;15(6):489–500.
   PubMed Web of Science ®Google Scholar
• Nadal E, Beer DG, Ramnath N. KRAS-G12C mutation is associated with poor outcome in surgically resected lung adenocarcinoma. J Thorac Oncol. 2015;10(2):e9–10.
   PubMed Web of Science ®Google Scholar
• Izar B, Zhou H, Heist RS, et al. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. J Thorac Oncol. 2014;9(9):1363–1369.
   PubMed Web of Science ®Google Scholar
• Renaud S, Falcoz PE, Schaëffer M, et al. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases. Br J Cancer. 2015 Oct 20;113(8):1206–1215.
   PubMed Web of Science ®Google Scholar
• Mascaux C, Iannino N, Martin B, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005;92:131–139.
   PubMed Web of Science ®Google Scholar
• Meng D, Yuan M, Li X, et al. Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: a systematic review with meta-analysis. Lung Cancer. 2013;81(1):1–10.
   PubMed Web of Science ®Google Scholar
• Pan W, Yang Y, Zhu H, et al. KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies. Oncotarget. 2016;7(7):8373–8388.
   PubMed Web of Science ®Google Scholar
• Schiller JH, Adak S, Feins RH, et al. Lack of prognostic significance of p53 and K-RAS mutations in primary resected non-small-cell lung cancer on e4592: a laboratory ancillary study on an eastern cooperative oncology group prospective randomized trial of postoperative adjuvant therapy. J Clin Oncol. 2001;19:448–457.
   PubMed Web of Science ®Google Scholar
• Mao C, Qiu LX, Liao RY, et al. KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer. 2010;69:272–278.
   PubMed Web of Science ®Google Scholar
• Hamilton M, Wolf JL, Rusk J, et al. Effects of smoking on the pharmacokinetics of erlotinib. Clin Cancer Res. 2006;12:2166–2171.
   PubMed Web of Science ®Google Scholar
• Zhu CQ, da Cunha Santos G, Ding K, et al. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol. 2008;26:4268–4275.
   PubMed Web of Science ®Google Scholar
• Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicenter, randomized, placebo-controlled phase 3 study. Lancet Oncol. 2010;11:521–529.
   PubMed Web of Science ®Google Scholar
• Miller VA, O’Connor P, Soh C, et al. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. 2009;27:abstract LBA8002.
   Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet. 2008;372:1809–1818.
   PubMed Web of Science ®Google Scholar
• Cadranel J, Mauguen A, Faller M, et al. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project–part 2). J Thorac Oncol. 2012 Oct;7(10):1490502.
   Web of Science ®Google Scholar
• Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol. 2007;25:5240–5247.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Domerg C, Hainaut P, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol. 2013;31(17):2173–2181.
   PubMed Web of Science ®Google Scholar
• Sun JM, Hwang DW, Ahn JS, et al. Prognostic and predictive value of KRAS mutations in advanced non-small cell lung cancer. PLoS One. 2013;8(5):e64816.
   PubMed Web of Science ®Google Scholar
• Metro G, Chiari R, Bennati C, et al. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014;15(1):86–92.
   PubMed Web of Science ®Google Scholar
• Macerelli M, Caramella C, Faivre L, et al. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer? Lung Cancer. 2014;83(3):383–388.
   PubMed Web of Science ®Google Scholar
• Cserepes M, Ostoros G, Lohinai Z, et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014;50(10):1819–1828.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Marabese M, Rusconi P, et al. Different types of KRas mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer. Ann Oncol. 2011;22:235–237.
   PubMed Web of Science ®Google Scholar
• Kim ES, Herbst RS, Wistuba II, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011;1:4453.
   Web of Science ®Google Scholar
• Renaud S, Schaeffer M, Voegeli AC, et al. Impact of EGFR mutations and KRAS amino acid substitution on the response to radiotherapy for brain metastasis of non-small-cell lung cancer. Future Oncol. 2016;12(1):59–70.
   PubMed Web of Science ®Google Scholar
• Wang M, Kern AM, Hülskötter M, et al. EGFR-mediated chromatin condensation protects KRAS-mutant cancer cells against ionizing radiation. Cancer Res. 2014;74(10):2825–2834.
   PubMed Web of Science ®Google Scholar
• Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13:1576–1583.
   PubMed Web of Science ®Google Scholar
• Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 2007;6:2209–2219.
   PubMed Web of Science ®Google Scholar
• Chen Z, Cheng K, Walton Z, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature. 2012;483:613–617.
   PubMed Web of Science ®Google Scholar
• Takahashi O, Komaki R, Smith PD, et al. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis. Clin Cancer Res. 2012 Mar 15;18(6):1641–1654.
   PubMed Web of Science ®Google Scholar
• Holt SV, Logie A, Odedra R, et al. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. Br J Cancer. 2012;106:858–866.
   PubMed Web of Science ®Google Scholar
• Meng J, Dai B, Fang B, et al. Combination treatment with MEK and AKT inhibitors is more effective than each drug alone in human non-small cell lung cancer in vitro and in vivo. PLoS One. 2010 Nov 29;5(11):e14124.
   PubMed Web of Science ®Google Scholar
• Holt SV, Logie A, Davies BR, et al. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). Cancer Res. 2012;72(7):1804–1813.
   PubMed Web of Science ®Google Scholar
• Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26:2139–2146.
   PubMed Web of Science ®Google Scholar
• Banerji U, Camidge DR, Verheul HM, et al. The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res. 2010;16:1613–1623.
   PubMed Web of Science ®Google Scholar
• Kim K, Infante J, Cohen R, et al. Abstract B225: A phase I dose-escalation study of selumetinib in combination with docetaxel in patients with advanced solid tumors. Mol Cancer Ther. 2011;10:B225.
   Google Scholar
• Dean E, Steele N, Arkenau H, et al. SELECT-3: A phase I study of selumetinib in combination with platinum doublet chemotherapy for advanced NSCLC in the first-line setting. Ann Oncol. 2016;27(6):416–454.
   Google Scholar
• Nicholas GA, Goffin JR, Laurie SA, et al. A phase Ib study of selumetinib in patients (pts) with previously untreated metastatic non-small cell lung cancer (NSCLC) receiving standard chemotherapy: NCIC clinical trials group IND.215. NCT01783197. J Clin Oncol. 2015;33(suppl; abstr 8046).
   Google Scholar
• Saka WO, Pacey S, Blackhall FH, et al. A phase I dose escalation study of the tolerability of the oral VEGFR and EGFR inhibitor vandetanib (V) in combination with the oral MEK inhibitor selumetinib (S) in solid tumors. J Clin Oncol. 2015;33(suppl; abstr 2583).
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Ramalingam SS, Ahn MJ, et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J Clin Oncol. 2015;33(suppl; abstr 2509).
   Google Scholar
• Hainsworth JD, Cebotaru CL, Kanarev V, et al. A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who have failed one or two prior chemotherapeutic regimens. J Thorac Oncol. 2010;5:1630–1636.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Khan K, Ong M, et al. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res. 2015 Feb 15;21(4):739–748.
   PubMed Web of Science ®Google Scholar
• Janne PA, Ghiorghiu DC, Smith PD, et al. SELECT-4: phase I dose escalation trial of selumetinib (AZD6244, ARRY-142886) in combination with durvalumab (MEDI4736) in patients with advanced solid tumors. J Clin Oncol. 2016; 34(suppl; abstr TPS2607). DOI: 10.1200/JCO.2016.34.15_suppl.TPS2607
   Web of Science ®Google Scholar
• Janne PA, Shaw AT, Pereira JR, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol. 2013;14:38–47.
   PubMed Web of Science ®Google Scholar
• Janne PA, Smith I, McWalter G, et al. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. Br J Cancer. 2015 Jul 14;113(2):199–203.
   PubMed Web of Science ®Google Scholar
• Carter CA, Rajan A, Keen C, et al. Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer. Ann Oncol. 2016;27(4):693–699.
   PubMed Web of Science ®Google Scholar
• Janne PA, van der Heuvel MM, Barlesi F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS-mutant advanced Non-Small Cell Lung Cancer: the SELECT-1 randomized clinical trial. JAMA. 2017;317:1844–1853.
   PubMed Web of Science ®Google Scholar
• Lopez-Chavez A, Thomas A, Rajan A, et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. J Clin Oncol. 2015;33:1000–1007.
   PubMed Web of Science ®Google Scholar
• Redig AJ, Jänne PA. Basket trials and the evolution of clinical trial design in an era of genomic medicine. J Clin Oncol. 2015;33(9):975–977.
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou V, Lee JJ, Wistuba II, et al. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non–small-cell lung cancer. J Clin Oncol. 2016;34:3638–3647.
   Web of Science ®Google Scholar
• Langsch S, Baumgartner U, Haemmig S, et al. miR-29b mediates NF-κB signaling in KRAS-induced non-small cell lung cancers. Cancer Res. 2016;76(14):4160–4169.
   PubMed Web of Science ®Google Scholar
• Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. Br J Cancer. 2015;112(1):95–102.
   PubMed Web of Science ®Google Scholar